Synonyms: BBR-2778 | Pixuvri®
pixantrone is an approved drug (EMA and UK (2012))
Compound class:
Synthetic organic
Comment: Pixantrone is an antineoplastic drug that also shows immunosuppressant activity [4-5]. It is administered clinically as pixantrone dimaleate (PubChem CID: 9937618).
|
|
No information available. |
Summary of Clinical Use ![]() |
Pixantronehas been studied as an antineoplastic for different kinds of cancer, with Phase 3 trials for solid tumours such as HER2-negative metastatic breast cancer and hematological malignancies such as non-Hodgkin lymphomas completed (see ClinicalTrials.gov for a full list of registered trials assessing this compound). In 2009 the EMA approved use of this drug under the conditions of its 'named patient' programme, for qualifying patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. This was promoted to full approval in 2012, and indicated for previously unresponsive non-Hodgkin's B-cell lymphoma. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Pixantrone acts as a topoisomerase II poison and intercalating agent [1-3]. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) European Medicines Agency (EMA) |